Related Experiment Videos
[Transcutaneous transport of trinitrin in children after application of nitroglycerin patches]
G Vaksmann1, E Rey, C Francart
1Service de Cardiologie Infantile, Hôpital Cardiologique, Lille.
Insights
Transdermal nitroglycerin bioavailability varies significantly in pediatric heart failure patients. Careful dosage titration is recommended, as initial doses may require adjustment based on individual tolerance and therapeutic effect.
Area of Science:
- Pharmacology
- Pediatric Cardiology
- Drug Delivery Systems
Context:
- Heart failure in children presents unique challenges for drug management.
- Transdermal drug delivery offers a potential alternative for continuous medication.
- Nitroglycerin is used to manage hemodynamic instability in pediatric patients.
Purpose:
- To evaluate plasma concentrations of nitroglycerin in pediatric patients with heart failure.
- To assess the bioavailability and variability of transdermal nitroglycerin in children.
- To determine the safety and efficacy of a specific nitroglycerin patch dosage regimen.
Summary:
- Plasma levels of nitroglycerin were measured in 7 children (1 month to 7 years) with heart failure 13-24 hours post-transdermal application.
- Significant inter-patient variability in plasma concentrations confirmed unpredictable transdermal nitroglycerin bioavailability in this pediatric cohort.
- Only 3 patients achieved nitremia >1 ng/mL, suggesting potential for hemodynamic effects, with no observed side effects at the initial dosage (1/4 patch per 5 kg).
Impact:
- Highlights the critical need for individualized dosing strategies for transdermal nitroglycerin in pediatric heart failure.
- Suggests that initial dosages may be insufficient, necessitating careful monitoring and progressive increases based on tolerance.
- Provides foundational data for optimizing transdermal nitroglycerin therapy in critically ill children.
Abstract:
Plasma levels of nitroglycerin were measured 13 to 24 hours after the application of nitroglycerin stamps in 7 children aged from 1 month to 7 years and suffering from heart failure. The plasma levels varied considerably from one patient to another, confirming that the bioavailability of transdermal nitroglycerin is extremely variable in children. Only 3 patients had a nitraemia higher than 1 ng/ml, a figure compatible with a haemodynamic effect of the drug. No side-effect associated with the nitroglycerin stamps was observed. The dosage we use (a quarter of a stamp for 5 kg bodyweight) seems to be adequate at the beginning of treatment, to be progressively increased according to the way the drug is tolerated.